PharmaShots | Incisive News in 3 Shots

Subscribe Now

shanghai henlius biotech

Shanghai Henlius Biotech Reports the Results of HLX01 (biosimilar, rituximab) in P-III Trial for the Treatment of Diffuse Large B-Cell Lymphoma

Shanghai Henlius Biotech Reports the Results of HLX01 (biosimilar, rituximab) in P-III Trial for the Treatment of Diffuse Large B-...

February 6, 2024

Shanghai Henlius Biotech Receives the NMPA’s IND Approval of HLX13 (biosimilar, ipilimumab) for the Treatment of Hepatocellular Carcinoma

Shanghai Henlius Biotech Receives the NMPA’s IND Approval of HLX13 (biosimilar, ipilimumab) for the Treatment of Hepatocellular Ca...

June 26, 2023

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

April 3, 2023

Insights+ Key Biosimilars Events of February 2023

Insights+ Key Biosimilars Events of February 2023

March 1, 2023

Shanghai Henlius Biotech Reports the First Patient Dosing of HLX15 (biosimilar, daratumumab) in P-I Clinical Trial for Multiple Myeloma

Shanghai Henlius Biotech Reports the First Patient Dosing of HLX15 (biosimilar, daratumumab) in P-I Clinical Trial for Multiple My...

February 3, 2023

Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the US

Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the U...

November 30, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us